港股異動|健世科技-B收漲15.87%創逾一年新高 機構指看好行業出海趨勢
健世科技-B(9877.HK)今日大幅收漲15.87%,收盤價報7.3港元,創逾一年新高。消息面上,中信建投此前發佈研報稱,展望2025年,繼續看好醫療器械行業自主可控及出海趨勢,可重點關注國內份額提升、受關稅衝擊影響較小及長期出海能力較強的公司。根據健世科技發佈的2024年財報,虧損1.78億元,較2023年大幅收窄52.2%,截至2024年12月31日,賬面貨幣資金7.08億元的充裕儲備,爲即將到來的商業化戰役以及其他產品臨牀試驗築牢護城河。分析指,2025年將成爲健世科技從研發驅動轉向商業化兌現的轉折年。短期,Ken-Valve正式進入商業化階段,公司將迎來首個業績兌現的關鍵節點。中長期,LuX-Valve Plus等產品有望向全球化價值鏈條延伸。(格隆匯)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.